The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
 
Branimir I. Sikic
Consulting or Advisory Role - Immune Design; Threshold Pharmaceuticals
Research Funding - Basilea (Inst); CellDex (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Sanofi (Inst)
 
Nehal J. Lakhani
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Amgen (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Forty Seven (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Sumit Shah
No Relationships to Disclose
 
Sreenivasa R Chandana
Honoraria - HERON
Consulting or Advisory Role - HERON
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Formation Biologics (Inst); Forty Seven (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
A. Dimitrios Colevas
Stock and Other Ownership Interests - Gilead Sciences; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Curis; Genentech
 
Timothy J. O'Rourke
Research Funding - Asana Biosciences (Inst)
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Genentech; Ipsen; Merck; Novartis
Consulting or Advisory Role - Genentech/Roche; ipsen; Merck
Research Funding - Aduro Biotech (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven; Stanford University
Travel, Accommodations, Expenses - Forty Seven
 
Balaji Agoram
Employment - Forty Seven; MedImmune
Stock and Other Ownership Interests - Forty Seven
 
James Y Chen
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
 
Jenny Huang
Employment - Forty Seven; Genentech/Roche
Stock and Other Ownership Interests - Forty Seven; Genentech/Roche
 
Matthew Axt
Employment - Forty Seven; Kaiser Permanente (I)
 
Ravindra Majeti
Employment - Genentech/Roche (I)
Leadership - Forty Seven
Stock and Other Ownership Interests - Amgen; Forty Seven; Roche
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Irving L. Weissman
Employment - Stem Cells, Inc. (I)
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Mark D. Pegram
Employment - Loxo (I)
Honoraria - Dava Oncology (I)
Consulting or Advisory Role - AstraZeneca; Genentech; Novartis; Pfizer
Travel, Accommodations, Expenses - DAVA Pharmaceuticals; Genentech; Novartis; Pfizer
Other Relationship - AstraZeneca; Genentech; Novartis; Pfizer
 
Sukhmani Kaur Padda
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; Janssen
Research Funding - EpicentRx (Inst); Forty Seven (Inst)